16 completed, 3 unknown, 1 terminated, 1 withdrawn. 8 Phase 4, 6 Phase 1, 3 Phase 2, 3 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 4, Unknown 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 3 | Completed 3 |
| Not applicable | 1 | Unknown 1 |
Follow Stalevo: new trials by email Literature Review of Stalevo trials Research Report on Stalevo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease levodopa/carbidopa/entacapone - Parkinson Disease | Phase 4 | Unknown | Second Affiliated Hospital of Soochow University | 60 | 2023-11-15 | 2024-02-01 |
| Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease Stalevo, Carbidopa and Levodopa Controlled Release Tablets - Parkinson Disease | Phase 4 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 180 | 2022-01-01 | 2023-02-16 |
| Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC) Stalevo, levodopa MR - Parkinson's Disease | Phase 2 | Completed | Orion Corporation, Orion Pharma | 84 | 2016-04-08 | 2018-04-05 |
| Pharmacokinetic Study in Healthy Volunteers levodopa, carbidopa, ODM-104, levodopa, carbidopa, entacapone - Parkinson's Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 15 | 2015-08-01 | 2016-01-14 |
| Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease Stalevo® - Parkinson Disease, Sleep Disorders | Not applicable | Unknown | Asan Medical Center | 100 | 2015-03-01 | 2016-07-13 |
| Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations ODM-101 65mg Carbidopa, ODM-101 105mg Carbidopa, Stalevo - Parkinson's Disease | Phase 2 | Completed | Orion Corporation, Orion Pharma | 117 | 2011-05-01 | 2013-11-21 |
| A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 IPX066, CLE - Parkinson's Disease | Phase 3 | Completed | Impax Laboratories, LLC | 110 | 2010-05-01 | 2019-10-29 |
| Levodopa Concentration Profile With Stalevo 75/125 mg Stalevo (levodopa/ carbidopa/ entacapone), Sinemet (levodopa/carbidopa) - Parkinson's Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 20 | 2009-12-01 | 2010-08-13 |
| Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off carbidopa/levodopa, Carbidopa/Levodopa/Entacapone - Parkinson's Disease | Phase 4 | Withdrawn | Novartis Pharmaceuticals | 2008-08-01 | 2012-04-30 | |
| Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa - Parkinson's Disease | Phase 4 | Terminated | Novartis | 14 | 2008-03-01 | 2011-02-18 |
| Study to Evaluate Initiation of Stalevo in Early Wearing-off Stalevo - Parkinson's Disease | Phase 4 | Completed | Orion Corporation, Orion Pharma | 115 | 2006-09-01 | 2015-04-21 |
| Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers ELC200 (carbidopa+levodopa+entacapone) - Healthy | Phase 1 | Completed | Novartis | 42 | 2006-07-01 | 2007-06-22 |
| Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone Under Fasting Conditions in Healthy Volunteers ELC200 (carbidopa+levodopa+entacapone) - Healthy | Phase 1 | Completed | Novartis | 42 | 2006-06-01 | 2007-06-22 |
| Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers ELC200 (carbidopa+levodopa+entacapone) - Healthy | Phase 1 | Completed | Novartis | 42 | 2006-06-01 | 2007-06-22 |
| Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers ELC200 (carbidopa+levodopa+entacapone) - Healthy | Phase 1 | Completed | Novartis | 42 | 2006-05-01 | 2007-06-22 |
| Stalevo in Early Wearing-Off Patients Stalevo (levodopa/carbidopa/entacapone), Levodopa/carbidopa - Idiopathic Parkinson's Disease | Phase 4 | Completed | Orion Corporation, Orion Pharma | 223 | 2005-08-01 | 2009-06-22 |
| A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) - Parkinson's Disease | Phase 3 | Completed | Novartis | 493 | 2005-08-01 | 2017-05-17 |
| Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States carbidopa, levodopa, entacapone - Parkinson's Disease | Phase 4 | Completed | Novartis | 184 | 2005-07-01 | 2017-03-29 |
| Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease Carbidopa/levodopa/entacapone - Parkinson's Disease With End of Dose Wearing Off | Phase 4 | Completed | Novartis Pharmaceuticals | 359 | 2005-01-01 | 2017-03-30 |
| Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa - Parkinson's Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 747 | 2004-09-01 | 2012-04-23 |
Showing 20 of 21. Sign in to see all of them.
Parkinson Disease (17) · Dyskinesias (2) · Fasting (1) · Narcolepsy (1) · Parasomnias (1) · Sleep Wake Disorders (1) · Tremor (1)
Novartis (7) · Orion Corporation, Orion Pharma (6) · Novartis Pharmaceuticals (3) · Asan Medical Center (1) · Impax Laboratories, LLC (1) · Molecular NeuroImaging (1) · Second Affiliated Hospital of Soochow University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
Germany (9) · Finland (5) · United States (5) · Italy (3) · Sweden (3) · United Kingdom (3) · Canada (2) · China (2) · France (2) · Turkey (Türkiye) (2) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · Denmark (1)
Aila Holopainen, MSc (1) · Andrew Wighton, BSc (Hons) (1) · Bhadravati SD Sastry, FRCP (1) · Chun-Feng Liu, MD,PhD (1) · Claudia Trenkwalder, MD (1) · John P Seibyl, MD (1) · Kimmo Ingman (1) · Mika Scheinin, MD (1) · Sun Ju Chung, Professor (1) · Wolfgang H. Oertel, Professor (1)